MeSH keywords: alcohol oxidoreductases • allergy and immunology • chemotactic factors • eicosanoid receptorsMetabolism of arachidonic acid by the 5-lipoxygenase pathway leads to the formation of leukotrienes including 5(S)-hydroxyeicosatetraenoic acid (5-HETE), which is oxidized by 5-hydroxyeicosanoid dehydrogenase to give 5-oxo-ETE (OXE), a potent chemoattractant primarily for eosinophils and also for neutrophils. The OXE receptor [1] is also expressed on monocytes, as well as on prostate tumor cells; antagonists might be useful as therapeutic or prophylactic agents for asthma [2], allergic rhinitis, chronic obstructive pulmonary disease, atopic dermatitis, psoriasis and certain cancers [3]. The inventors, who have published extensively on the subject, had reported 5-(6-chloro-2-hexyl-1H-indol-1-yl)-5-oxo-valeric acid as an OXE antagonist lead compound with an IC 50 of 400 nM [4]. Further refinements using a structure-based approach in which substituents mimicking the essential polar (C1-C5) and hydrophobic (C15-C20) regions of OXE were incorporated in an indole scaffold, had identified racemic compounds with IC 50 values below 30 nM, widely disparate between the stereoisomers [5]. In the present patent application, the limits have been pushed much further: (S)-5-(5-chloro-2-(6-(3-chlorophenyl)hexyl)-1-methyl-1H-indol-3-yl)-3-methyl-5-oxopentanoic acid has an IC 50 of 8 pM. When administered to cynomolgus monkeys at a dose of either 5 mg/kg or 2 × 5 mg/kg 8 h apart, it was found converted to a single polar metabolite that also showed potent OXE antagonistic activity.